Substance P: Structure, function, and therapeutics

Current Topics in Medicinal Chemistry

Volumn 4, Issue 1, 2004, Pages 75-103

  Datar, Prasanna ^a   Srivastava, Sudha ^b   Coutinho, Evans ^a   Govil, Girjesh ^b  

^a BOMBAY COLLEGE OF PHARMACY   (India)

^b TATA INSTITUTE OF FUNDAMENTAL RESEARCH   (India)

Author keywords

2D NMR; NK receptor; NK1 antagonists; QSAR; SAR of SP; Secondary structure; Substance P

Indexed keywords

2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; [1 (1H INDOL 3 YLMETHYL) 1 METHYL 2 OXO 2 [(1 PHENYLETHYL)AMINO]ETHYL]CARBAMIC ACID BENZO[B]FURAN 2 YLMETHYL ESTER; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; CAM 4092; ELEDOISIN; FR 113680; GR 71251; LANEPITANT; MDL 103392; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NEUROKININ 1 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; NEUROKININ B; NEUROPEPTIDE GAMMA; NEUROPEPTIDE K; NOLPITANTIUM; PHYSALAEMIN; SCH 206272; SUBSTANCE P; SUBSTANCE P ANTAGONIST; SUBSTANCE P DERIVATIVE; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR AGONIST; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZD 6021; DRUG DERIVATIVE; PEPTIDE FRAGMENT;

ANTIHYPERTENSIVE ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTINOCICEPTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIRCULAR DICHROISM; DEPRESSION; DRUG ACTIVATION; DRUG CONFORMATION; DRUG DESIGN; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; GENETIC ORGANIZATION; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PROTEIN FUNCTION; PROTEIN STRUCTURE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURE ACTIVITY RELATION; VOMITING; AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROTEIN SECONDARY STRUCTURE;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, NEUROKININ-1; RECEPTORS, NEUROKININ-2; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTANCE P;

EID: 2142758070     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451636     Document Type: Review

References (292)

1. Hökfelt, T.; Broberger, C.; Xu, D. Z.; Sergeyev, V.; Ubink, R.; Diez, M. Neuropeptides-an overview, Neuropharmacology 2000, 39, 1337-1356.
2. von Euler, U.S.; Gaddum, J. H., An unidentified depressor substance in certain tissue extracts. J. Physiol. 1931, 72, 74-87.
3. Hökfelt, T.; Pernow, B.; Wahren, J. Substance P: a pioneer amongst neuropeptides. J. Intern. Med. 2001, 249, 27-40.
4. Maggio, J.E. Tachykinins. Ann. Rev. Neurosci. 1988, 11, 13-28.
5. DeVane C.L. Substance P: A New Era, A New Role. Pharmacotherapy 2001, 21, 1061-1069.
6. Vaught, J.L. Substance P antagonists and analgesia: a review of the hypothesis. Life Sci. 1988, 43, 1419-1431.
7. Chang, M.M, Leeman, S.E., Niall, H.D. Amino Acid Sequence of Substance P. Nature New Biol. 1971, 232, 86-87.
8. Erspramer, V.; Anastasi, A. Structure and pharmacological actions of eledoisin, the active endecapeptide of the posterior salivary glands of Eledone. Experientia 1962, 18, 58-59.
9. Erspamer, V.; Anastasi, A.; Bertaccini, G.; Cei, J.M. Structure and pharmacological actions of physalaemin, the main active polypeptide of the skin of physalaemus fuscumaculatus. Experientia 1964, 20, 489-490.
10. Anastasi, A.; Falconieri E. G. Occurrence of phyllomedusin, a physalaemin-like decapeptide in the skin of Phyllomedusa bicolor. Experientia 1970, 26, 866-67.
11. Anastasi, A.; Montecucchi, P.; Erspamer, V.; Visser, J. Amino acid composition and sequence of kassinin, a tachykinin dodecapeptide from the skin of African frog Kassinia senegalensis. Experientia 1977, 33, 857-58.
12. Kimura, S.; Okada, M.; Sugita, Y.; Kanazawa, I.; Munekata, E. Novel neuropeptides, neurokinins A and B, isolated from porcine spinal cord. Proc. Jpn. Acad. 1983, 56, 101-104.
13. Kangawa, K.; Minamino, N.; Fukuda, A.; Matsuo, H. Neuromedin K. A novel mammalian tachykinin identified in porcine spinal cord. Biochem. Biophys. Res. Commun. 1983, 114, 533-540.
14. Kage, R.; Me Gregor, G.P.; Thim, L.; Conlon, J.M. Neuropeptide-γ: A peptide isolated from rabbit intestine that is derived from γ-Preprotachykinin. J. Neurochem. 1988, 50, 1412-1417.
15. Tatemoto, K.; Lundberg, J.M.; Jörnvall, H.; Mutt, V. Neuropeptide K: Isolation, structure and biological activities of a novel brain tachykinin. Biochem. Biophys. Res. Commun. 1985, 128, 947-953.
16. Anastasi, A.; Erspamer, V.; Endean, R.; Structure of uperolein, a physalaemin like endecapeptide occurring in the skin of Uperleia rugosa, and Uperoleia marmorata. Experientia, 1975, 31, 394-395.
17. Maggi, C. A. The troubled story of tachykinins and neurokinins. Trends Pharmacol. Sci. 2000, 21, 173-175.
18. Henry, J. L. Discussion of nomenclature for tachykinins and tachykinin receptors. In Substance P and Neurokinins, Henry, J.L.; Couture, R.; Cuello, A.C.; Pelletier, G.; Quirion, R.; Regoli, D. (Eds.); Springer-Verlag, 1987, pp xvii.
19. Iverson, L.L.; Watling, K.J.; McKnight, A.T.; Williams, B.J.; Lee, C.M. Multiple receptors for substance P and related tachykinins. In Topics in Medicinal Chemistry: The Proceedings of the 4th SCIRSC Medicinal Chemistry Symposium, Leeming, P.R., Eds.; Royal Society of Chemistry, London, 1988; pp. 1-9.
20. Nawa, T.; Hirose, T.; Takashima, H.; Inayama, S.; Nakanishi, S. Nucleotide sequences of cloned cDNA for two types of bovine brain SP precursor. Nature, 1983, 306, 32-36.
21. Nawa, T.; Kotani, H.; Nakanishi, S. Tissue specific generation of two preprotachykinin mRNAs from one Gene by Alternative RNA Splicing. Nature (London), 1984, 312, 729-734.
22. Bonner, T.; Affolter, H.U.; Young, A.C.; Young, W.S. A cDNA encoding the precursor of the rat neuropeptide neurokinin B. Mol. Brain. Res. 1987, 2, 243-249.
23. Kotani, H.; Hoshimaru, M.; Nawa, H.; Nakanishi, S. Structure and gene organization of bovine neuromedin K precursor. Proc. Natl. Acad. Sci. USA. 1986, 83, 7074-7078.
24. Nakanishi, S. Substance P precursor and kininogen: their structures, gene organizations, and regulations. Physiol. Rev. 1987, 67, 1117-1142.
25. MacDonald, M. R.; Takeda, J.; Rice, C. M.; Krause, J. E. Multiple tachykinins are produced and secreted upon post translational processing of the three substance P precursors proteins, α, α b-, and γ-preprotachykinin. Expression of the preprotachykinins in AtT-20 cells infected with vaccinia virus recombinants. J. Bio. Chem. 1989, 264, 15578-15592.
26. Wang, Y.; Bockman, C.S.; Lovas, S.; Abel, P. W.; Murphy, R.F.; Conlon, J. M. Neuropeptide γ-[1-9] peptide: A major product of the posttranslational processing of γ-preprotachykinin in rat tissues. J. Neurochem. 1993, 61, 1231-1235.
27. Carter, M. S.; Krause, J.E. Structure, expression, and some regulatory mechanism of the rat preprotachykinin gene encoding substance P, neurokinin A, neuropeptide K, and neuropeptide γ. J. Neurosci. 1990, 10, 2203-2214.
28. Harmar, A. J.; Armstrong, A.; Pascall, J.C.; Chapman, K.; Rosie, R.; Curtis, A.; Going, J.; Edwards, C.R.W.; Fink, G. cDNA sequence of human β-preprotachykinin, the common precursor to substance P and neurokinin A. FEBS Lett. 1986, 208, 67-72.
29. Kako, K.; Munekata, E.; Hosaka, M.; Murakami, K.; Nakayama, K. Cloning and sequence analysis of mouse cDNAs encoding preprotachykinin A and B. Biomed. Res. 1993, 14, 253-259.
30. Lavielle, S.; Chassaing, G.; Loeuillet, D.; Convert, O.; Torrens, Y.; Beaujouan, J. C.; Saffroy, M.; Petiet, F.; Bergström, L.; Glowinski, J. Selective agonists of tachykinin binding sites. Fundam. Clin. Pharmacol. 1990, 4, 257-269.
31. Buck, S.H.; Burcher, E. The Tachykinins: A family of peptides with a "Brood" of Receptors. Trends Pharmacol. Sci. 1986, 7, 65-68.
32. Ohkubo, H.; Nakanishi, S. Molecular Characterization of the Three Tachykinin Receptors. Annu. Rev. N. Y. Acad. Sci. 1991, 632, 53-62.
33. 125I] Bolton Hunter derivatives of Eledoisin and substance P in the rat brain. Neuroscience 1986, 18, 857-875.
34. Laufer, R.; Gilon, C.; Chorev, M.; Selinger, Z.; Characterization of a Neurokinin B Receptor Site in Rat Brain using a highly selective Radioligand. J. Biol. Chem. 1986, 261, 10257-10263.
35. Mori, M.; Yokota, Y.; Yasue, M.; Serikawa, T.; Yamada, J. Assignment of the genes coding for substance P receptor, substance K receptor, and neuromedin K receptor to chromosomes 4, 20, 2, respectively. Cytogenet. Cell. Genet. 1992, 60, 222-223.
36. Gerard, N. P.; Eddy, R.L.; Shows, T. B.; Gerard, C. The human neurokinin A (substance K) receptor: molecular cloning of the gene, chromosome localization, and isolation of cDNA from tracheal and gastric tissues. J. Biol. Chem. 1990, 265, 20455-20462.
37. 1): organization of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry 1991, 30, 10640-10646.
38. Kris, R. M.; South, V.; Salzman, A.; Felder, S.; Ricca, G.A.; Jaye, M.; Huebner, K.; Kagan, J.; Croce, C. M.; Schlessinger, J. Cloning and expression of the human substance K receptor and analysis of its role in mitogenesis. Cell. Growth. Differ. 1991, 2, 15-22.
39. Butcher, E.; Mussap, C. J.; Geraghty, D. P; McClure-Sharp, J. M.; Watkin, D. J. Concents in the characterization of tachykinin receptors. Ann. N. Y. Acad. Sci. 1991, 632, 123-136.
40. 3H] senktide. Brain Res. 1990, 506, 175-179.
41. Dam, T. V.; Takeda, Y.; Krause, J.E.; Escher, E.; Quirion, R. γ-Preprotachykinin (72-92)-peptide amide. An endogeneous preprotachykinin I gene-derived peptide that preferentially binds to neurokinin-2 receptors. Proc. Natl. Acad. Sci. USA. 1990, 87, 246-250.
42. Gerard, N. P.; Bao, L.; Ping, H. X.; Gerard, C. Molecular aspect of the tachykinin receptors. Regul. Pept. 1993, 43, 21-23.
43. Maggi, C.A. The mammalian tachykinin receptors. Gen. Pharmacol. 1995, 26, 911-944.
44. Pattachini, R.; Maggi, C.A. Tachykinin receptors and receptor subtypes. Arch. Int. Pharmacodyn. Ther. 1995, 329, 161-184.
45. 1 receptor. Trends Pharmacol. Sci. 1997, 18, 351-355.
46. Masu, Y.K.; Nakayama, H.; Tamaki, Y.; Harada, M.; Nakanishi, K.S.; cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature, 1987, 329, 836-838.
47. Dam, T.V.; Quirion, R. Pharmacological Characterization and autoradiographic localization of Substance P receptors in guinea pig brain. Peptides 1986, 7, 855-864.
48. Danks, J.A.; Rothman, R.B.; Cascieri, M.A.; Chicchi, G.G.; Liang, T.; Herkenham, M. A. Comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. Brain Res. 1986, 385, 273-281.
49. 3 ligands) in the rat brain. Peptides 1988, 9, 227-241.
50. Sivam, S.P.; Krause, J.E.; Tachykinin systems in the spinal cord and basal ganglia: influence of neonatal capsaicin treatment or dopaminergic intervention on levels of peptides, substance P-encoding mRNAs, and substance P receptor mRNA. J. Neurochem. 1992, 59, 2278-2284.
51. 1 receptor expression by cholinergic interneurons in human striatum. Neuro Report 1994, 5, 1597-1600.
52. Whitty, J.W.; Walker, P.D.; Goebel, D.J.; Poosch, M.S.; Bannon, M.J.; Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra. Neuroscience 1995, 64, 419-425.
53. Whitty, C.J.; Paul, M.A.; Bannon, M.J. Neurokinin receptor mRNA localization in human midbrain dopamine neurons. J. Comp. Neurol. 1997, 382, 394-400.
54. Shigemoto, R.; Nakaya, Y.; Nomura, S.; Ogawa-Meguro, R.; Ohishi, H.; Kaneko, T.; Nakanishi, S.; Mizuno, N. Immunocytochemical localization of rat substance P receptor in the striatum, Neurosci. Lett. 1993, 153, 157-160.
55. Brown, E.R.; Harlan, R.E.; Krause, J. E. Gonadal steroids regulation of substance P (SP) and SP-encoding messenger ribonucleic acids in the rat anterior pituitary and hypothalamus. Endocrinology 1990, 126, 330-340.
56. Otsuka, M.; Yoshioka, K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 1993, 73, 229-308.
57. Quartara, L.; Maggi, C.A. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides 1998, 32, 1-49.
58. Patacchini, R.; Maggi, C.A. Peripheral tachykinin receptors as targets for new drugs. Eur. J. Pharmacol. 2001, 429, 13-21.
59. Evangelista, S. Involvement of tachykinins in intestinal inflammation. Curr. Pharm. Des. 2001, 7, 19-30.
60. 1 tachykinin receptor. Med. Res. Rev. 1996, 16, 297-317.
61. Quartara, L.; Maggi, C.A. The tachykinin NK1 receptor: Part I. Ligands and Mechanisms of cellular activation. Neuropeptides 1997, 31, 537-563.
62. Maggi, C.A.; Giuliani, S.; Santicioli, P.; Regoli, D.; Meli, A. Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors. J. Auton. Pharmacol. 1987, 7, 11-32.
63. Lippe, C.; Lobasso, S.; Cassano, G.; Bellantuono, V.; Ardizzone, C. Actions of tachykinins on the ion transport across the frog skin. Peptides 1998, 19, 1435-1438.
64. Mantyh, C.R.; Gates, T.S.; Zimmerman, R.P.; Welton, M. L.; Passaro, E.P.; Vigna, S.R.; Maggio, J.E.; Kruger, L.; Mantyh, P.W. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentration by arterioles, venules and lymph nodes in surgical specimens obtained from patients with ulcerative colitis and Crohn's disease. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 3235-3239.
65. Lundburg, J.M.; Saria, A. Capsaicin-sensitive vagal neurons involved in control of vascular permeability in rat trachea. Acta Physiol. Scand. 1982, 115, 521-523.
66. Joos, G.F.; Germonpré, P.R.; Pauwels, R.A. Role of tachykinins in asthma. Allergy 2000, 55, 321-337.
67. Joos, G. F.; De Swert, K.O.; Pauwels, R.A. Airway inflammation and tachykinins: prospects for the development of tachykinin receptor antagonists. Eur. J. Pharmacol. 2001, 429, 239-250.
68. Skerrett, P.J. Substance P causes pain-but also heals. Science 1990, 249, 625.
69. Regoli, D.; Escher, E.; Mizrahi, J. Substance P-structure activity studies and the development of antagonists. Pharmacology 1984, 28, 301-320.
70. Kramer, M.S.; Cutler, N.; Feighner, J. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998, 281, 1640-1645.
71. Cao, Y.Q.; Mantyh, P.W.; Carlson, E.J.; Gillespie, A.M.; Epstein, C.J.; Basbaum, A.I.; Primary afferent tachykinins are required to experience moderate to intense pain. Nature 1998, 392, 390-394.
72. Lotz, M.; Vaughan, J.H; Carson, D.A. Effect of Neuropeptides on Production of Inflammatory Cytokines by Human Monocytes. Science 1988, 241, 1218-1221.
73. Dickerson, C.; Undem, B.; Bullock, B.; Winchurch, R.A. Neuropeptide regulation of proinflammatory cytokine responses. J. Leukoc. Biol. 1998, 63, 602-605.
74. Perianin, A.; Snyderman, R.; Malfroy, B. Sustance P Primes Human Neutrophil Activation: A Mechanism for Neurological Regulation of Inflammation. Biochem. Biophys. Res. Commun. 1989, 161, 520-524.
75. Baruch, P.; Artaud, F.; Godeheu, G.; Barbeito, L; Glowinski, J.; Cheramy, A. Substance P and Neurokinin A Regulate by Different Mechanisms Dopamine Release from Dendrites and Nerve Terminals of the Nigrostriatal Dopaminergic Neurons. Neuroscience 1988, 25, 8889-8898.
76. Tang, F.I.; Chiu, T.H.; Wang, Y. Electrochemical studies of the effects of substance P on dopamine terminals in the rat striatum. Exp. Neurol. 1998, 152, 41-49.
77. Role, L. W.; Leeman, S.E.; Perlman, R.L. Somatostatin and SP inhibit catecholamine secretion from isolated cells of guinea pig adrenal medulla. Neurosci. 1981, 6, 1813-1821.
78. Kohlmann, O. Jr.; Cesaretti, M.L.; Ginoza, M.; Role of Substance P in Blood Pressure regulation in salt-dependent experimental hypertension. Hypertension 1997, 29, 506-509.
79. Sakuma, M.; Yashioka, K.; Yanagisawa, M.; Onishi, Y.; Otsuka, M. Tachykinins induce a release of acetylcholine from neonatal rat spinal cord. Jpn. J. Pharmacol. 1990, 52, (Suppl. 1) 143p.
80. Lowman, M.A.; Benyon, R.C.; Church, M.K. Characterization of neuropeptide induced histamine release from dispersed skin mast cells. Br. J. Pharmacol. 1988, 95, 121-130.
81. +; Veratridine, or electrical stimulation from rat cortical slices. J. Neurochem. 1979, 32, 1565-1573.
82. Leboulenger, F.; Vaglini, L.; Conlon, J.M.; Homo-Delarche, F.; Wang, Y.; Kerdelhue, B.; Pelletier, G.; Vaudry, H.; Immunohistochemical distribution, biochemical characterization and biologic action of tachykinins in the frog adrenal gland. Endocrinology 1993, 133, 1999-2008.
83. Radhakrishnan, V.; Henry, J.L. Electrophysiology of neuropeptides in the sensory spinal cord. Prog. Brain Res. 1995, 104, 175-195.
84. Lieberman, D.N.; Mody, I. Substance P enhances NMDA channel function in hippocampal dentate gyrus granule cells. J. Neurophysiol. 1998, 80, 113-119.
85. Dixon, R.A.F.; Strader, C.D.; Sigal, L.S. Structure and function of G-protein coupled receptors. In Annual Reports in Medicinal Chemistry, Allen, R.C.; Eds.; Academic Press: New York. 1988; 23, 221-233.
86. O'Dowd, B.F.; Lefkowitz, R.J.; Caron, M.G.; Structure of the Adrenergic and related Receptors. Annu. Rev. Neurosci. 1989, 12, 67-83.
87. Bonner,T. I. The molecular basis of muscarinic receptor diversity. Trends Neurosci. 1989, 12, 148-151.
88. Shigemoto, R.; Yokota, Y.; Tsuchida, K.; Nakanishi, S. Cloning and Expression of a Rat neuromedin K receptor cDNA. J. Biol. Chem. 1990, 265, 623-628.
89. Nakanishi, S.; Ohkubo, H.; Kakizuka, A.; Yokota, Y.; Shigemoto, R.; Sasai, Y.; Takumi, I. Molecular characterization of mammalian tachykinin receptors and a possible epithelial potassium channel. Recent Prog. Horm. Res. 1990, 46, 59-84.
90. Dixon, R.A.F.; Sigal, S.; Candelore, N.R.; Scathergood, W.; Rands, E.; Strader, C.D. Structural features required for ligand binding to the β-adrenergic receptor. EMBO J. 1987, 6, 3269-3275.
91. 2-adrenergic receptor. J. Biol. Chem. 1989, 264, 7564-7569.
92. Sundelin, J.B.; Provvedini, D.M.; Wahlestedt, C.R.; Laurell, H.; Pohl, J.S.; Peterson, P.A. Molecular cloning of the murine substance K and substance P receptor genes. Eur. J. Biochem. 1992, 203, 625-631.
93. Gorbulev, V. Akhundova, A.; Luzius, H.; Fahrenholz, F. Molecular cloning of substance P receptor cDNA from guinea-pig uterus. Biochim. Biophys. Acta. 1992, 1131, 99-102.
94. 1 receptor in the brain: Pharmacology and Putative Functions. Eur. J. Pharmacol. 1999, 375, 51-60.
95. Fong, T.M.; Yu, H.; Strader, C.D. Molecular basis for the species selectivity of the neurokinin-1 receptor antagonist CP-96345. J. Biol. Chem. 1992, 267, 25668-25671.
96. Sachais, B.S.; Snider, R.M.; Lowe, J.A.; Krause, J.A.; Molecular basis for the species selectivity of the substance P antagonist CP-96, 345. J. Biol. Chem. 1993, 268-2319-2323.
97. Hastrup, H.; Schwartz, T.W. Septide and neurokinin A are high-affinity ligands on the NK-1 receptor: evidence from homologous versus heterologous binding analysis. FEBS Lett. 1996, 399, 264-266.
98. 1 tachykinin receptor of a domain involved in recognition of neurokinin A and septide but not of substance P. FEBS Lett. 1999, 447, 155-159.
99. Bremer, A.A.; Leeman, S.E.; Boyd, N.D. Evidence for spatial proximity of two distinct receptor regions in the substance P (SP)* neurokinin-1 receptor (NK-1R) complex obtained by photolabeling the NK-1R with p-benzoylphenylalanine3-SP. J. Biol. Chem. 2001, 276, 22857-22861.
100. 1 receptor revealed by G-protein fusions and mutagenesis. J. Biol. Chem. 2001, 276, 19793-19799.
101. Hershey, A.D.; Polenzani, L.; Woodward, R.M.; Miledi, R.; Krause, J.E. Molecular and Genetic Characterization, Functional, Expression, and mRNA Expression Patterns of a Rat Substance P Receptor. Ann. N. Y. Acad. Sci. 1991, 632, 63-78.
102. Nathans, J.; Hogness, D.S. Isolation and nucleotide sequence of the gene encoding human rhodopsin. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 4851-4855.
103. Nathans, J.; Thomas, D.; Hogness, D.S, Molecular genetics of human color vision: the genes encoding blue, green, and red pigments. Science 1986, 232, 193-202.
104. Grandy, D.K.; Marchionni, M.A.; Makam, R.E.; Siofko, M.; Alfano, L.; Froihinoham, J.B.; Fischer, K.J.; Burke-Howie, J.R.; Bunzow, A.; Server, C.; Civelli, O. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9762-9766.
105. O'Malley, K.L.; Mack, K.J.; Gandelman, K.Y.; Todd, R.D. Organization and expression of the rat D2A receptor gene: identification of alternative transcripts and a variant donor splice site. Biochemistry 1990, 29, 1367-1371.
106. Douglass, J.; Civelli, O.; Herbert, E. Polyprotein gene expression: generation of diversity of neuroendocrine peptides. Annu. Rev. Biochem. 1984, 53, 665-715.
107. Traut, T.W. Do exons code for structural or functional units in proteins? Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 2944-2948.
108. Sheng, M.; Dougan, S.T.; McFadden, G.; Greenberg, M.E. Calcium and growth factor pathways of c-fos transcriptional activation require distinct upstream regulatory sequences. Mol. Cell Biol. 1988, 8, 2787-2796.
109. Roesler, W.J.; Vandenbark, G.R.; Hanson, R.W. Cyclic AMP and the induction of eukaryotic gene transcription. J. Biol. Chem. 1988, 263, 9063-9066.
110. Abdel-Latif, A. A. Calcium-mobilizing receptors, polyphosphoinositides, and the generation of second messengers. Pharmacol. Rev. 1986, 38, 227-272.
111. Sugiya, H. J.; Obie, F.; Putney Jr, J.W. Two modes of regulation of the phospholipase C-linked substance-P receptor in rat parotid acinar cells. Biochem. J. 1988, 253, 459-466.
112. Hanley, M.R.; Lee, C.M.; Jones, L.M.; Michell, R.H. Similar effects of substance P and related peptides on salivation and on phosphatidylinositol turnover in rat salivary glands. Mol. Pharmacol. 1980, 18, 78-83.
113. Wiess, S.J.; McKinney, J.S.; Putney Jr., J.W. Receptor-mediated net breakdown of phosphatidylinositol 4,5-bisphosphate in parotid acinar cells. Biochem. J. 1982, 206, 555-560.
114. Putney Jr, J.W. Muscarinic, alpha-adrenergic, and peptide receptors regulate the same calcium influx sites in the parotid gland. J. Physiol. (London). 1977, 268, 139-149.
115. Garland, A.M.; Grady, E.F.; Payan, D. G.; Bunnett, N. W. Mechanisms regulating the responsiveness of cells to substance P: cell-surface degradation of substance P and NK1 receptor endocytosis. Biomed. Res. 1994, 15 (Suppl.2): 5-13.
116. Grady, E.F.; Garland, A.M.; Gamp, P.D.; Lovett, M.; Payan, D.G.; Bunnett, N.W. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol. Biol. Cell. 1995, 6, 509-524.
117. Vigna, S. R. The N-terminal domain of substance P is required for complete homologous desensitization but not phosphorylation of the rat neurokinin-1 receptor. Neuropeptides 2001, 35, 24-31.
118. Yokota, Y.C.; Akazawa, H.; Ohkubo, H.; Nakanishi, S. Delineation of structural domains involved in the subtype specificity of tachykinin receptors through chimeric formation of substance-P substance-K receptors. EMBO J. 1992, 11, 3585-3591.
119. Nielsen, S.M.; Elling, C.E.; Schwartz, T.W. Split-receptors in the tachykinin neurokinin-1 system-mutational analysis of intracellular loop 3. Eur. J. Biochem. 1998, 251, 217-226.
120. Elling, C.E.; Nielsen, S.M.; Schwartz, T.W. Conversion of antagonist-binding site in the tachykinin NK-1 receptor. Nature 1995, 374, 74-77.
121. Elling, C.E.; Thirstrup, K.; Nielsen, S.M.; Hjorth, S.A.; Schwartz, T.W. Engineering of metal-ion sites as distance constraints in structural and functional analysis of 7TM receptors. Fold. Des. 1997, 2, S76-80.
122. Elling, C.E.; Schwartz, T.W. Connectivity and orientation of the seven helical bundle in the tachykinin NK-1 receptor probed by zinc site engineering. EMBO. J. 1996, 15, 6213-6219.
123. 3 receptor. FEBS Lett. 1998, 439, 35-40.
124. Strader, C.D. The view from Inside the Receptor. J. Med. Chem. 1996, 39, 1.
125. 1 receptor on antagonist affinity. Eur. J. Pharmacol. 1997, 337, 73-81.
126. Fong, T.M.; Cascieri, M.A.; Yu, H.; Bansal A.; Swain C.; Strader C.D. Amino-aromatic interaction between histidine 197 of neurokinin-1 receptor and CP 96,345. Nature 1993, 362, 350-353.
127. 1 receptor for substance P and a non-peptide antagonist. Nature 1993, 362, 345-348.
128. 1 receptor regulates tachykinin selectivity and receptor conformation. FEBS Lett. 1997, 416, 335-338.
129. 1 receptor. Mol. Pharmacol. 1998, 53, 166-175.
130. Josien, H.; Lavielle, S.; Brunissen, A.; Saffroy, M.; Torrens, Y.; Beaujouan, J.; Glowinski, J.; Chassaing, G. Design and Synthesis of Side-Chin Conformationally Restricted Phenylalanines and Their Use for Structure-Activity Studies on Tachykinin NK-1 Receptor. J. Med. Chem. 1994, 37, 1586-1601.
131. Sagan, S.; Josien, H.; Karoyan, P.; Brunissen, A.; Chassaing, G.; Lavielle, S. Tachykinin NK-1 receptor probed with constrained analogues of substance P. Bioorg. Med. Chem. 1996, 4, 2167-2178.
132. Bremer, A.A.; Leeman, S.E.; Boyd, N.D. The common C-terminal sequences of substance P and neurokinin A contact the same region of the NK-1 receptor. FEBS Lett. 2000, 486, 43-48.
133. Cascieri, M.A.; MacLeod, A.M.; Underwood, D.; Shiano, L.L.; Strader, C.D.; Fong, T.M. Characterization of the interaction of N-Acyl-L-Tryptophan Benzyl Ester Neurokinin Antagonists with the Human Neurokinin-1 Receptor. J. Biol. Chem. 1994, 269, 6587-6591.
134. Fong, T.M.; Yu, H.; Cascieri, M.A.; Underwood, D.; Swain, C.; Strader, C.D. Interaction of Glutamine 165 in the Fourth Transmembrane Segment of the Human Neurokinin-1 Receptor with Quinuclidine Antagonists. J. Biol. Chem. 1994, 269, 14957-14961.
135. Greenfeder, S.; Cheewatrakoolpong, B.; Billah, M.; Egan, R.W.; Keene, E.; Murgolo, N.J.; Anthes, J.C. The neurokinin-1 and neurokinin-2 receptor binding sites of MDL103,392 differ. Bioorg. Med. Chem. 1999, 7, 2867-2876.
136. 3 receptors suggest a role for an inhibitory domain in determining receptor specificity. J. Biol. Chem. 1996, 271, 20250-20257.
137. Fisher, G.H.; Folkers, K.; Pernow, B.; Bowers, C.Y. Synthesis and Some Biological Activities of the Tyrosine-8 Analog of Substance P. J. Med. Chem. 1976, 19, 325-328.
138. Mroz, E.A.; Leeman, S.E. Substance P. Vitam. Horm. 1977, 35, 209-281.
139. Yanaihara, N.; Yanaihara, M.; Hirohashi, M.; Sato, H.; Iizuka, Y.; Hashimoto, T.; Sakagami, M. In Substance P; U.S. Euler, V.; Pernow, B.; Eds.; Raven Press: New York, 1977; pp 83-88.
140. Couture, R.; Fournier, A.; Magnan, J.; St-Pierre, S.; Regoli, D. Structure-activity studies on substance P. Can. J. Physiol. Pharmacol. 1979, 57, 1427-1436.
141. Fournier, A.; Couture, R.; Regoli, D.; Gengreau, M.; St-Pierre, S. Synthesis of Peptides by the Solid-Phase Method. 7. Substance P and Analogues. J. Med. Chem. 1982, 25, 64-68.
142. Folkers, K.; Håkanson, R.; Hörig, J. Jie-cheng X.; Leander, S. Biological evaluation of substance P antagonists. Br. J. Pharmac. 1984, 83, 449-456.
143. Folkers, K.; Rosell, S.; Jie-cheng, X.; Björkroth, U.; Yi-an, L.; Yinzeng, L. Antagonists of substance P from emphasis on position 11. Acta Chem. Scand. 1983, B37, 623-627.
144. Post, C.; Folkers, K. Behavioural and antinociceptive effects of intrathecally injected substance P analogues in mice. Eur. J. Pharmac. 1985, 113, 335-343.
145. Young, S.S.; Hawkins, D.M. Analysis of a 29 Full Fractional Chemical Library. J. Med. Chem. 1995, 38, 2784-2788.
146. Sachon, E.; Girault-Lagrange, S.; Chassaing, G.; Lavielle, S.; Sagan, S. Analogs of Substance P modified at the C-terminus which are both agonist and antagonist of the NK-1 receptor depending on the second messenger pathway. J. Pept. Res. 2002, 59, 232-240.
147. Norinder, U.; Rivera, C.; Unden, A. A Quantitative Structure-activity Relationship Study Of some substance P-related peptides. A multivariate approach using PLS and variable selection. AADE Ed J. 1997, 49, 155-162.
148. Becker, O.M.; Levy, Y.; Ravitz, O. Flexibility, Conformation Spaces, and Bioactivity. J. Phys. Chem. B. 2000, 104, 2123-2135.
149. Chassaing, G.; Convert, O.; Lavielle, S. Preferential conformation of substance P in solution. Eur. J. Biochem. 1986, 154, 77-85.
150. Wooley, G.A.; Deber, C.M. Peptides in membranes: lipid-induced secondary structure of substance P. Biopolymers 1987, 26, S109-S121.
151. Convert, O.; Ploux, O.; Lavielle, S.; Cotrait, M.; Chassaing, G. Analysis of tachykinin-binding site interaction using NMR and energy calculations data of potent cyclic analogues of substance P. Biochim. Biophysica. Acta 1988, 954, 287-302.
152. Convert, O.; Duplaa, H.; Lavielle, S.; Chassaing, G. Influence of the replacement of amino acid by its D-enantiomer in the sequence of substance P. 2. Conformational analysis by NMR and energy calculations. Neuropeptides 1991, 19, 259-270.
153. Sumner, S.C.J.; Gallagher, D.G.D.; Covell, D.G.; Jernigan, R.L.; Ferretti, J.A. Conformational Analysis of the Tachykinins in Solution: Substance P and Physalaemin. J. Biomol. Struct. Dyn. 1990, 8, 687-707.
154. Cowsik, S.M.; Lücke, C.; Rüterjans, H. Lipid-induced Conformation of Substance P. J. Biomol. Struct. Dyn. 1997, 15, 27-36.
155. Teleman, O.; Lieth, C.V.D. Molecular Dynamics Simulation Provides a Possible Structure for Substance P-Like Peptides in Aqueous Solution. Biopolymers 1990, 30, 13-23.
156. Manavalan, P.; Momany, F.A. Conformational energy calculations on substance P. Int. J. Pept. Prot. Res. 1982, 20, 351-365.
157. Nikiforovitch, G.V.; Baoodis, Y.; Chippens, G. I. In Peptides: Proceedings of the 16th European Peptide Symposium; Brunfeldt, K. Ed.; Scriptor Inc. Copenhagen, 1980, pp. 631-636.
158. Cotrait, M.; Hospital, M. Conformational behaviour of some tachykinin C-terminal heptapeptides. Int. J. Pept. Res. 1986, 28, 450-455.
159. 2. Biochem. Biophys. Res. Comm. 1982, 109, 1123-1128.
160. Cotrait, M. Conformational study of the neurotensin and substance P fragments: Pro-Arg-Arg-Pro and Arg-Pro-Lys-Pro. Int. J. Pept. Prot. Res. 1983, 22, 110-118.
161. Szollosy, A.; Otter, A.; Stewart, J.M.; Kotovych, G. An NMR study of the conformations of N-terminal substance P fragments and antagonists. J. Biomol. Struct. Dyn. 1986, 4, 501-519.
162. Chassaing, G.; Convert, O.; Lavielle, S.; Ploux, O. In Substance P and Neurokinins; Henry, J.L.; Couture, R.; Cuello, A.C.; Pelletier, G.; Quirion, R.; Regoli, D.; Eds.; Springer-Verlag: New York, 1987, pp 63-65.
163. Kawaki, H.; Otter, A.; Beierbeck, H.; Kotovych, G.; Stewart, J. M. The conformational analysis of substance P analogs using high-field NMR techniques. J. Biomol. Struct. Dyn. 1986, 3, 795-803.
164. Shukla D.R.; Mahajan, S. In Proteins; Krishnan, R; Ed.; ESCOM: Leiden, Netherlands, 1991; pp 85-95.
165. Otter, A.; Kotovych, G. Two dimensional C-13 NMR study of the substance P fragment Arg-Pro-Lys-Pro. J. Magn. Reson. 1987, 74, 293-307.
166. Fong, T.M.; Yu, H.; Huang, R.R.C.; Strader, C.D. The extracellular domain of the Neurokinin-1 Receptor is Required for High affinity Binding of Peptides. Biochemistry 1992, 31, 11806-11811.
167. 1) Receptor from P388D1 Cells with Photolabile Agonists. J. Biol. Chem. 1995, 270, 1213-1220.
168. Huang, R.R.C.; Yu, H.; Strader, C.D.; Fong, T.M. Interaction of Substance P with the Second and Seventh Transmembrane Domains of the Neurokinin-1 Receptor. Biochemistry 1994, 33, 3007-3013.
169. Schwyzer, R.; Erne, D.; Rolka, K. Membrane Structure of Substance P. I. Prediction of Preferred Conformation, Orientation, and Accumulation of Substance P on Lipid Membranes. Helv. Chim. Acta 1986, 69, 1789-1797.
170. Schwyzer, R. Membrane-assisted molecular mechanism of neurokinin receptor subtype selection. EMBO J. 1987, 6, 2255-2259.
171. William, R.W.; Weaver, J.L. Secondary Structure of Substance P Bound to Liposomes in Organic Solvents and in Solution from Raman and CD Spectroscopy. J. Biol. Chem. 1990, 265, 2505-2513.
172. Wu, C.C.; Yang, J.T. Conformation of naturally-occurring peptides in surfactant solution: its relation to the structure-forming potential of amino acid sequence. Biochem. Biophys. Res. Commun. 1978, 82, 85-91.
173. Wu, C.C.; Yang, J.T. Sequence-dependent conformations of short polypeptides in a hydrophobic environment. Mol. Cell Biochem. 1981, 40, 109-122.
174. Wu, C.S.C.; Hachimori, A.; Yang, J.T. Lipid-induced ordered conformation of some peptide hormones and bioactive oligopeptides: predominance of helix over beta form. Biochemistry 1982, 21, 4556-4562.
175. Rolka, K.; Erne, D.; Schwyzer, R. Membrane s tructure of substance P. II. Secondary structure of substance P,[9-leucine] substance P, and shorter segments in 2,2,2-trifluoromethanol, methanol, and on liposomes studied by circular dichroism. Helv. Chim. Acta 1986, 69, 1798-1806.
176. Sandberg, B.E. B.; Iverson, L.L. Substance P. J. Med. Chem. 1982, 25, 1009-1015.
177. Koziej, P.; Mutter, M.; Gremlich, H. U.; Hoelzemann, G. Conformational studies of synthetic polyethylene glycol-bound substance P and its lower analogs. Z. Naturforsch. 1985, 40B, 1570-1774.
178. Young, J.K.; Anklin, C.; Hicks, R.P. NMR and Molecular Modeling Investigations of the Neuropeptide Substance P in the Presence of 15mM Sodium Dodecyl Sulphate Micelles. Biopolymers 1994, 34, 1449-1462.
179. Seelig, J.; Macdonald, P.M. Phospholipids and proteins in Biological membranes. H-2 NMR as a method to study structure. Acc. Chem. Res. 1987, 20, 221-228.
180. Hicks, R.P.; Beard, D.J.; Young, J.K. The Interaction of Neuropeptides with Membrane Model System: A Case Study. Biopolymers 1992, 32, 85-96.
181. 1 Receptor. J. Med. Chem. 1998, 41, 1497-1506.
182. Seelig, A.; Macdonald, P.M. Binding of a Neuropeptide, Substance P, to Neutral and Negatively Charged Lipids. Biochemistry 1989, 28, 2490-2496.
183. Bradshaw, J.P.; Davies, S.M.A.; Hauss, T. Interaction of substance P with Phospholipid Bilayers: A Neutron Diffraction Study. Biophys. J. 1998, 75, 889-895.
184. Keire, D.A.; Fletcher, T.G. The conformation of substance P in lipid environments. Biophys. J. 1996, 70, 1716-1727.
185. Grdadolnik, S.G.; Mierke, D.F.; Byk, G.; Zeltser, I.; Gilon, C.; Kessler, H. Comparison of the Conformation of Active and Nonactive Backbone Cyclic Analogs of Substance P as a Tool To Elucidate Features of the Bioactive Conformation: NMR and Molecular Dynamics in DMSO and Water. J. Med. Chem. 1994, 37, 2145-2152.
186. Kothekar, V. 260ps Molecular Dynamics Simulation of Substance P With Hydrated Dimyristoyl Phosphatidyl Choline Bilayer. J. Biomol. Struct. Dyn. 1996, 601-612.
187. Kamath, S.; Coutinho, E. Conformation of the C-terminal pentapeptide-the 'message sequence'-of tachykinins as determined by consensus dynamics. J. Biosci. 1997, 22, 315-324.
188. 7-11). Ind. J. Biochem. Biophys. 1997, 34, 435-448.
189. Coutinho, E.; Kamath, S.; Saran, A.; Srivastava, S. NMR and Molecular Dynamics Studies of Tachykinins: Conformation of Substance P Fragment 4-11. J. Biomol. Struct. Dyn. 1998, 16, 747-755.
190. Saran, A.; Srivastava, S.; Coutinho, E.; Kamath, S. A Comparison of the Conformation of an Eledoisin Related Peptide and the. C-terminal Peptide of Substance P by NMR and MD Simulations. Physiol. Chem. Phys. & Med. NMR 1998, 30, 63-79.
191. Coutinho, E.; Srivastava, S.; Saran, A. Influence of N-terminal Residues on the Conformation of the "Message" Sequence of Tachykinins. In Perspectives in Structural Biology; Vijayan, M.; Yathindra, N.; Kolaskar, A.S.; Eds.; Indian Academy of Sciences, Universities Press: Hyderbad, India, 1999; pp 511-517.
192. 8-SP Alters the Conformation of the Peptide in DMSO, Water, and Lipid Bilayers. Biopolymers 1999, 50, 602-612.
193. Swain, C.; Rupniak, N. M. J. Progress in the development of neurokinin aantagonists. Annu. Rep. Med. Chem. 1999, 34, 51-60.
194. 2 receptor antagonists. Drugs Future 1999, 24, 883-892.
195. Gao, Z.; Peet, N.P. Recent advances in neurokinin receptor antagonists. Curr. Med. Chem. 1999, 6, 375-388.
196. Sakurada, T.; Sakurada, C.; Tan-No, K.; Kisara, K. Neurokinin receptor antagonists: therapeutic potential in the treatment of pain syndromes. CNS Drugs 1997, 8, 436-447.
197. Folkers, K.; Horig, J.; Rosell, S.; Bjorkroth, U. Chemical design of antagonists of substance P. Acta Physiol. Scand. 1981, 111, 505-506.
198. Folkers, K.; Resell, S.; Chu, J.Y.; Lu, L.A.; Tang, P.F.L.; Ljungqvist, A.; Design and Synthesis of Antagonists of Substance P. Acta Chem. Scand, 1986, B40, 295-302.
199. Dutta, A.S.; Gormley, J.J.; Graham, A.S.; Briggs, I.; Growcott, J.W.; Jamieson, A. Analogues of substance P. Peptides containing D-amino acid residues in various positions of substance P and displaying agonist or receptor selective antagonist effects. J. Med. Chem. 1986, 29, 1163-1171.
200. Folkers, K.; Feng, D. M.; Asano, N.; Håkanson, R.; WeisenfeldHalline, Z.; Leander, S.; Spantide II, an Effective Tachykinin Antagonist Having High Potency and Negligible Neurotoxicity. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 4833-4835.
201. William, B.J.; Curtis, N.R.; Mcknight, A.T.; Maguire, J.J.; Young, S.C.; Veber, D. F.; Baker, R.; Cyclic Peptides as Selective Tachykinin Antagonists. J. Med. Chem. 1993, 36, 2-10.
202. Hagiwara, D.; Miyake, H.; Morimoto, H.; Murai, M.; Fujii, T.; Matsuo, M. Studies on Neurokinin Antagonist 1. The Design of Novel Tripeptides Possessing the Glutaminyl- D-tryptophylphenylalanine sequence as Substance P Antagonists. J. Med. Chem. 1992, 35, 2015-2025.
203. α-Acetyl-L-threonyl)-N′-formyl-D-tr yptophyl]-N-methyl-N-(phenylmethyl)-L-phenylalaninamide and Its Related Compounds. J. Med Chem. 1992, 35, 3184-3191.
204. 1 Receptor Selectivity. Br. J. Pharmacol. 1992, 106, 123-126.
205. α-(Substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamide as Substance P antagonists. J. Med. Chem. 1993, 36, 2266-2278.
206. 1 Receptor. J. Med. Chem. 1994, 37, 1269-1274.
207. Fujii, T.J. Murai, M.; Morimoto, H.; Maeda, Y.; Yamaoka, M.; Hagiwara, D. J.; Miyake, H.; Ikari, N.; Matsuo, M.; Pharmacological Profile of a High Affinity Dipeptide NK Receptor Antagonist; FK888. Br. J. Pharmacol. 1992, 107, 785-789.
208. Torigoe, K.; Sofuku, S.; Sato, H.; Muramarsu, I. In Peptides Chemistry 1981, Shioiri, T. Ed.; Protein Research Foundation: Osaka, Japan, 1982; pp 71-74.
209. Horwell, D.C.; Howson, W.; Ratcliffe, G.S.; Willems, H.M. The design of dipeptide helical mimetics: the synthesis, tachykinin receptor affinity and conformational analysis of 1,1,6-trisubstituted indanes. Bioorg. Med. Chem. 1996, 4, 33-42.
210. 1 Antagonists: Conformationally Constrained Heterocyclic Bioisosteres of the Ester Linkage. J. Med. Chem. 1995, 38, 923-944.
211. 1 Receptor Antagonists. J. Med. Chem. 1996, 39, 736-748.
212. 1 Receptor Antagonist. J. Med. Chem. 2001, 44, 2276-2285.
213. 1 Receptor Antagonists. Bioorg. Med. Chem. 1994, 2, 357-370.
214. Gellman, S.H.; Dado, G.P.; Liang, G.B.; Adams, B.R. Conformation-Directing Effects of a Single Intramolecular Amide-Amide Hydrogen bond: Variable-Temperature NMR and IR Studies on a Homologous Diamide Series. J. Am. Chem. Soc. 1991, 113, 1164-1173.
215. Millet, R.; Goossens, L.; Bertrand-Caumont, K.; Goossens, J.F.; Houssin, R.; Hénichart, J.P. A flexible approach to the design of new potent substance P receptor ligands. J. Pharm. Pharmacol. 2001, 53, 929-934.
216. Toniolo, C. Conformational Restricted Peptides Through Short Range Cyclization. Int. J. Pept. Protein Res. 1990, 35, 287-300.
217. Lavielle, S.; Chassaing, G.; Besseure, J.; Julein, S.; Loeuillet, D.; Marquet, A.; Beaujouan, J. C.; Berström, L.; Torrens, Y.; Glowinski, J. Tachykinin Receptors. In Peptides: Chemistry and Biology, Proceedings of the Tenth American Peptide Symposium; Marshall, G. R.; Ed.; ESCOM: Leiden, 1988; pp 482-483.
218. Freidinger, R. M.; Scwenk, D.A.; Veber, D.F. One-Step Synthesis of an Ion Binding Peptide by Cyclotrimerization of a Lactam Containing Dipeptide. In Peptides: Structure and Biological Function, Proceedings of the Sixth Americal Peptide Symposium; Gross, E. Meienhofer, J., Eds.; Pierce Chem. Co.: Rockford, 1983; pp703-706.
219. Manavalan, P.; Momany, F.A. Conformational Energy Studies on N-Methylated Analogs of Thyrotropin Releasing Hormone. Biopolymers 1980, 19, 1943-1973.
220. Ward, P.; Ewan, G. B.; Jordan, C.C.; Ireland, S. J.; Hagan, R. M.; Brown, J. R. Potent and highly selective Neurokinin antagonists. J. Med. Chem. 1990, 33, 1848-1851.
221. 1 Selective, N-Backbone Cyclic Analogs of the C-Terminal Hexapeptide of Substance P. J. Med. Chem. 1996, 39, 3174-3178.
222. Wormser, U.; Laufer, R.; Hart, Y.; Chorey, M.; Gilon, C.; Selinger, Z. Highly selective agonists for Substance P receptor subtypes. EMBO J. 1986, 5, 2805-2808.
223. 1 Receptor Ligand via a Polyvalent Pepidomimentic. J. Med. Chem. 1996, 39, 2441-2448.
224. 1 Tripeptide Antagonists: A Proton Nuclear Magnetic Resonance Study. J. Med. Chem. 1997, 40, 594-601.
225. 1 Receptor. Farmaco 1995, 50, 755-761.
226. 1) Receptor. Science 1991, 251, 435-437.
227. Garret, C.; Carruette, A.; Fardin, V.; Moussaoui, S.; Peyronel, J.F.; Blanchard, J.C.; Laduron, P.M. Pharmacological Properties of a Potent and Selective Nonpeptide Substance P Antagonist, Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 10208-10212.
228. Maggi, C.A.; Patacchini, R.; Rovero, P.; Giachetti, A. Tachykinin Receptors and Tachykinin Receptor Antagonists, J. Auton. Pharmacol. 1993, 13, 23-93.
229. Regoli, D.; Boudon, A.; Fauchere, J.L. Receptor and Antagonists for Substance P and related Peptides. Pharmacol. Rev. 1994, 46, 551-599.
230. Lowe, J.A. III; Drozda, S.E.; Snider, R.M.; Longo, K.P.; Zorn, S.H.; Morreone, J.; Jackson, E.R.; McLean, S.; Bryce, D.K.; Bordner, J.; Nigahisa, A.; Kanai, Y.; Suga, O.; Tsuchiya, M. The discovery of(2S,3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl) methyl]-1-azabicyclo[2.2.2]-octane-3-amine as a Novel, Nonpeptide Substance P Antagonist. J. Med. Chem. 1992, 35, 2591-2600.
231. Yokota, Y.; Sasai, Y.; Tanaka, K.; Fujiwara, T.; Tsuchida, K.; Shigemoto, R.;Kakizuka, A.; Ohkubo, H.; Nakanishi, S. Molecular Characterization of a Functional cDNA for Rat Substance P Receptor. J. Biol. Chem. 1989, 264, 17649-17652.
232. Ariens, E. J.; Beld, A.J.; Rodrigues de Miranda, J.F.; Simonis, A. M. In The Receptor: A Comprehensive Treatise, O'Brien, R. D., Eds.; Plenum: New York, 1979; 1, 33-91.
233. Appell, K.C.; Babb, B. E.; Goswami, R.; Hall, P.L.; Lawrence, K.B.; Venepalli, B.R.; Yanni, J. M.; Imidazo[4,5-b]quinoxaline Cyanines as Neurokinin Antagonists. J. Med. Chem. 1991, 34, 1751-1753.
234. Venepalli, B.R.; Aimone, L. D.; Appell, K.C.; Bell, M.R.; Dority, J.A.; Goswami, R.; Hall,P.L.; Kumar, V.; Lawrence, K. B.; Logan, M. E.; Scensny, P.M.; Seelye, J.A.; Tomczuk, B. E.; Yanni, J.M. Synthesis and Substance P Receptor Binding Activity of Androstano[3,2-b]pyrimido[1,2-a]benzimidazoles. J. Med. Chem. 1992, 35, 374-378.
235. Desai, M.C., Lefkowitz, S.L.; Thadeio, P.F.; Longo, K.P.; Snider, R. M.; Discovery of a Potent Substance P Antagonist: Recognition of the Key Molecular Determinant. J. Med. Chem. 1992, 35, 4911-4913.
236. Lawrence, K.B.; Venepalli, B.R.; Appell, K.C.; Goewami, R.; Logan, M.E.; Tomczuk, B.E.; Yanni, J.M. Synthesis and Substance P Antagonist Activity of Naphthimidazolium Derivatives. J. Med. Chem. 1992, 35, 1273-1279.
237. Lowe III, J.A.; Drozda, S.E.; McLean, S.; Bryce, D.K.; Crawford, R.T.; Snider, R.M.; Longo, K.P.; Nagahisa, A.; Tsuchiya, M. Aza-Tricyclic Substance P Antagonists. J. Med. Chem. 1994, 37, 2831-2840.
238. 1 Receptor. Neuropeptides 1993, 24, 233.
239. 1 Antagonist: The Triarylperhydroisoindolols. Bioorg. Med. Chem. Lett. 1994, 4, 673-676.
240. Mills, S.G.; Wu,M.T.; MacCoss, M.; Budhu, R.J.; Dorn, C.P.; Cascieri, M.A.; Sadowski, S.; Strader, C.D.; Greenlee, W. J.; 1,4-Diacylpiperazine-2-(S)-[(N-Aminoalkyl) carboxamides] as Novel Potent Substance P Receptor Antagonists. Bioorg. Med. Chem. Lett. 1993, 3, 2707-2712.
241. 1 Antagonist. J. Med. Chem. 1995, 38, 1264-1266.
242. Schilling, W.; Bittiger, H.; Bragger, F.; Criscione, L.; Hauser, K.; Ofner, S.; Olpe, H.R.; Vassout, A.; Veenstra, S.; Approaches Towards the Design and Synthesis of Nonpeptidic Substance P Antagonists. XIIth International Symposium on Medicinal Chemistry, Basel, September 1992, Abstract ML-11.3.
243. 1 Antagonists. J. Med. Chem. 1996, 39, 2907-2914.
244. Anthes, J.; Chapman, R.; Richard, C.; Eckel, S.; Corboz., M.; Hey, J.; Fernandez, X.; Greenfeder, S.; McLeod, R.; Sehring, S.; Rizzo, C.; Crawley, Y.; Shih, N.; Piwinski, J.; Reichard, G.; Ting, P.; Carruthers, N.; Cuss, F.; Billah, M.; Kreutner, W.; Egan, R. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist. Eur. J. Pharmacol. 2002, 450, 191.
245. Natsugari, H.; Ikeura, Y.; Kiyota, Y.; Ishichi, Y.; Ishimaru, T.; Saga, O.; Shirafuji, H.; Tanaka, T.; Kamo, I.; Doi, T.; Otsuka, M. Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyrido[3,4-b]pyridine. J. Med. Chem. 1995, 38, 3106-3120.
246. 1 Receptor Antagonists: synthesis and antagonistic Activity of Various Heterocycles with an N-[3,5-Bis(trifluoromethyl benzyl]-N-methylcarbamoyl substituent. Chem. Pharm. Bull. 1997, 45, 1642-1652.
247. 1 Receptor Antagonists: Determination of the Absolute Stereochemical Requirements. J. Med. Chem. 1998, 41, 4232-4239.
248. 1 Receptor Antagonists: Synthesis, Antagonistic Activity, and Effects on Bladder Functions. J. Med. Chem. 1999, 42, 3982-3993.
249. 1 Tachykinin Receptor Antagonist with Good Oral Analgesic Activity in Chronic Pain Models. J. Med. Chem. 1998, 41, 3159-3173.
250. Gray, R.A,; Vander Velde, D.G.; Burke, C. J.; Manning, M. C.; Middaugh, C. R.; Borchardt, R.T. Delta-Sleep-Inducing Peptide: Solution Conformational Studies of a Membrane-Permeable Peptide. Biochemistry 1994, 33, 1323-1331.
251. Yamagami, C.; Takami, H.; Yamamoto, K.; Miyoshi, K.; Takao, N. Hydrophobic Properties of Anticonvulsant Phenylacetanilides. Relationships between Octanol-Water Partition Coefficient and Capacity Factor Determined by Reversed Phase Liquid Chromatography. Chem. Pharm. Bull. 1984, 32, 4994-5002.
252. Hale, J.J.; Mills, S.G.; MacCoss, M.; Finke, P.E.; Cascieri, M.A.; Sadowski, S.; Ber, E.; Chicchi, G.G.; Kurtz, K.; Metzger, J. Eiermann, G.; Tsou, N.N.; Tattersall, F.D. Rupniak, N.M.J.; Williams, A.R.; Rycroft, W.; Hargreaves, H.; MacIntyre, D.E. Structural Optimization Affording 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl) phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl) methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist. J. Med. Chem. 1998, 41, 4607-4614.
253. Hale, J.J.; Mills, S.G.; MacCoss, M.; Shah, S.K.; Qi, H.; Mathre, D.J.; Cascieri, M.A.; Sadowski, S.; Strader, C.D.; MacIntyre, D.E.; Metzger, J.M. 2(S)-((3,5-Bis(trifluoromethyl)benzyl)-oxy) -3(S)-phenyl-4-((3-oxo-1,2,4-triazol-5-yl)methyl) morpholine (1): A Potent, Orally Active, Morpholine-Based Human Neurokinin-1 Receptor Antagonist. J. Med. Chem. 1996, 39, 1760-1762.
254. Hashimoto, M.; Hayashi, K.; Murai, M.; Fujii, T.; Nishikawa, M.; Kiyoto, S.; Okuhara, M.; Kohsaka, M.; Imanaka, H. WS9326A, a novel tachykinin antagonist isolated from Streptomyces violaceusniger no. 9326. II. Biological and pharmacological properties of WS9326A and tetrahydro-WS9326A (FK224) J. Antibiot. 1992, 45, 1064-1070.
255. Barrow, C.J.; Sun, H.H. Spiroquinazoline, a novel substance P inhibitor with a new carbon skeleton, isolated from Aspergillus flavipes. J. Nat. Prod. 1994, 57, 471-476.
256. 1 Receptor Antagonist Isolated from the Plants of Compositae. Chem. Pharm. Bull. 1997, 50, 47-52.
257. Adenier, C.; Joos, G.; Molimard, M.; Lagante, V.; Pauwels. R. Role of tachykinins as contractile agonists of human airways in asthma. Clin. Exp. Allergy 1999, 29, 579-584.
258. Barnes, P.J.; Baraniuk, J.N.; Belvisi, M.G. Neuropeptides in respiratory tract. Part I. Am. Rev. Respir. Dis. 1991, 144, 1187-1198.
259. Albert, J.S.; Aharony, D.; Andisik, D.; Barthlow, H.; Bernstein, P. R.; Bialecki, R. A.; Dedinas, R.; Dembofsky, B.T.; Hill, D.; Kirkland, K.; Koether, G. M.; Kosmider, B. J.; Ohnmacht, C.; Palmer, W.; Potts, W.; Rumsey, W.; Shen, L.; Shenvi, A.; Sherwood, S.; Warwick, P. J.; Russell, K. Design, synthesis, and SAR of tachykinin antagonists: modulation of balance in NK(1)/NK(2) receptor antagonist activity. J. Med. Chem. 2002 45, 3972-3983.
260. 2 receptor antagonists. Bioorg. Med. Chem. Lett. 1997, 7, 2531-2536.
261. Kudlacz, E.M.; Knippenberg, R.W.; Shatzer, S.A.; Kehne, J.H.; McCloskey, T.C.; Burkholder, T.P. The peripheral NK-1/NK-2 receptor antagonist MDL 105,172A inhibits tachykinin-mediated respiratory effects in guinea-pigs. J. Auton. Pharmacol. 1997, 17, 109-119.
262. 2 tachykinin receptor antagonists: synthesis and structure-activity relationships of novel oxazolidine analogues. Bioorg. Med. Chem. Lett. 1999, 9, 875-880.
263. 2 receptors. Abstr. Pap.-Am. Chem. Soc. 2000,220, MEDI-195.
264. 2dual antagonists. Bioorg. Med. Chem. Lett. 2000, 10, 2329-2332.
265. 2 antagonists. Bioorg. Med. Chem. Lett. 2001, 11, 2769-2773.
266. 2 inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 491-494.
267. 1 antagonists as observed in their crystal structures. Bioorg. Med. Chem. 1997, 5, 535-547.
268. 1 Tachykinin Antagonists: A Comparison of Classical QSARs, and Three-Dimentional QSARs from Similarity Matrices. J. Med. Chem. 1995, 38, 4454-4462.
269. Takeuchi, Y.; Shands, E.F.B.; Beusen, D.D.; Marshall, G.R. Derivation of a Three-Dimentional Pharmacophore Model of Substance P Antagonists Bound to the Neurokinin-1 Receptor. J. Med. Chem. 1998, 41, 3609-3623.
270. 1 (substance P) receptor antagonists-why are they not analgesic in humans? Trends Pharmacol. Sci. 2000, 21, 244-246.
271. 1)-receptor antagonists ineffective in pain treatment? Anaesthesist. 2002, 51, 308-319.
272. Han, X.Y.; Saria, A.;Gamse, R.; Theodorsson, N.E.; Brodin, E.; Lundberg, J.M. Capsaicin induced release of multiple tachykinins ( substance P, neurokinin A, and eledoisin-like material) from guinea pig spinal cord and ureter. Neuroscience 1986, 19, 313-319.
273. 1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord. Br. J. Pharmacol. 1994, 113, 635-641.
274. Longmore, J.; Hill, R.G.; Hargreaves, R.J. Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can. J. Physiol. Pharmacol. 1997, 75, 612-621.
275. Lotz, M.; Carson, D.A.; Vaughan, J.H; Substance P Activation of Rheumatoid Synoviocytes: Neural Pathway in Pathogenesis of Arthritis. Science 1987, 235, 893-895.
276. Moskowitz, M. A. Neurogenic Versus Vascular mechanisms of Sumatriptan and Ergot Alkaloids in Migraine. Trends Pharmacol. Sci. 1992, 13, 307-311.
277. Coudore, C.M.A.; Courteix, C.; Eschalier, A.; Fialip, J. Effect of tachykinin receptor antagonists in experimental neuropathic pain. Eur. J. Pharmacol. 1998, 361, 175-184.
278. Rupniak, N.M.J.; Hill, R.G. In Novel Aspects of Pain Management: Opioids and Beyond; Sawynok, J. Cowan, A.; Eds.; John Wiley Press, 1999, pp 135-155.
279. Goldstein, D. J.; Wang, O.; Saper, J.R.; Stoltz, R.; Silberstein, S.D.; Mathew, N.T. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study, Cephalalgia. 1997, 17, 785-790.
280. Teixeira, R.M.; Santos, A.R.; Ribeiro, S.J.; Calixto, J.B.; Rae, G.A.; De Lima, T.C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol. 1996, 311, 7-14.
281. 1) antagonists. Trends Pharmacol. Sci, 1999, 20, 495-490.
282. Stout, S.C.; Owens, M.J.; Nemeroff, C.B.; Neurokinin(1) receptor antagonists as potential antidepressants. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 877-906.
283. Diemunsch, P.; Grelot, L. Potential of substance P antagonists as antiemetics. Drugs 2000, 60, 533-546.
284. 1 receptor antagonists in chemotherapy-induced nausea and vomiting. Support Care Cancer 2001, 9, 350-354.
285. 1 receptor in the development of allergen-induced airway hyperreactivity and airway inflammation in conscious, unrestrained guinea pigs. Am. J. Respir. Crit. Care. Med. 1999, 159, 423-430.
286. Joos, G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi. Arch. Chest, Dis. 2000, 55, 411-414.
287. Joos, G.F.; Pauwels, R.A. Tachykinin receptor antagonists: potential in airways diseases. Curr. Opin. Pharmacol. 2001, 1, 235-241.
288. Reynolds, P.N.; Scicchitano, R.; Holmes, M.D. Pre-protachykinin-A mRNA is increased in the airway epithelium of smokers with chronic bronchitis. Respirology 2001, 6, 187-197.
289. Rogers, D.F. Pharmacological regulation of the neuronal control of airway mucus secretion. Curr. Opin. Pharmocol. 2002, 2, 249-255.
290. Moreaux, B.; Nemmar, A.; Vincke, G.; Halloy, D.; Beerens, D.; Advenier, C.; Gustin, P. Role of substance P and tachykinin receptor antagonists in citric acid-induced cough in pigs. Eur. J. Pharmacol. 2000, 408, 305-312.
291. 1 receptors. Br. J. Cancer 1999, 79, 236-243.
292. 1 receptor antagonists on human glioma U373 MG xenograft. Br. J. Cancer 2000, 82, 480-487.